Ken Griffin
GLMD icon

Ken Griffin’s Galmed Pharmaceuticals GLMD Stock Holding History

Ken Griffin’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5K Sell
11,382
-26,795
-70% -$18.1K ﹤0.01% 12812
2025
Q4 		$28.7K Sell
38,177
-12,315
-24% -$14.4K ﹤0.01% 12236
2025
Q3 		$71.2K Buy
+50,492
New +$81.1K ﹤0.01% 12027
2024
Q1 		– Sell
-938
Closed -$5.12K – 14886
2023
Q4 		$5.12K Sell
938
-2,434
-72% -$11.6K ﹤0.01% 13452
2023
Q3 		$25.1K Buy
+3,372
New +$44.7K ﹤0.01% 12432
2023
Q2 		– Sell
-227
Closed -$17.4K – 14660
2023
Q1 		$17.4K Buy
+227
New +$24.4K ﹤0.01% 13157
2022
Q4 		– Sell
-103
Closed -$6K – 15080
2022
Q3 		$6K Sell
103
-228
-69% -$19.5K ﹤0.01% 12346
2022
Q2 		$41K Buy
331
+261
+373% +$43.3K ﹤0.01% 12046
2022
Q1 		$20K Buy
+70
New +$19.8K ﹤0.01% 13238
2021
Q4 		– Sell
-156
Closed -$78K – 14165
2021
Q3 		$78K Sell
156
-63
-29% -$33K ﹤0.01% 13084
2021
Q2 		$120K Buy
+219
New +$119K ﹤0.01% 12743

Other funds holding GLMD

Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Ken Griffin's GLMD Position: Q1 2026 in Review

Ken Griffin reduced its Galmed Pharmaceuticals (GLMD) stake by 70% in Q1 2026, selling an estimated $18.1K and leaving 11,382 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12812.

Ken Griffin first reported a position in GLMD in Q2 2021 and has held it in 11 quarters since. The position peaked at $120K in Q2 2021. 16 funds tracked by Wall St. Rank hold GLMD as of Q1 2026.

  • Ken Griffin held 11,382 shares of Galmed Pharmaceuticals worth $5.5K as of Q1 2026.
  • Ken Griffin sold 26,795 Galmed Pharmaceuticals shares in Q1 2026, an estimated $18.1K.
  • Galmed Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12812 holding.
  • Ken Griffin first reported a position in Galmed Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • Ken Griffin's Galmed Pharmaceuticals position peaked at $120K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.